Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: Analysis of a primary-care database

Current Medical Research and Opinion

Volumn 30, Issue 4, 2014, Pages 655-665

  Jameson, Kevin ^a   Zhang, Qiaoyi ^b   Zhao, Changgeng ^b   Ramey, Dena Rosen ^b   Tershakovec, Andrew M ^b   Gutkin, Stephen W ^c   Marrett, Elizabeth ^b  

^a Merck Sharp & Dohme Limited   (United Kingdom)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Rete Biomedical Communications Corp   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Cholesterol; Diabetes; Drug therapy; Statins

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; CHOLESTEROL; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FAMILIAL HYPERCHOLESTEROLEMIA; HIGH RISK PATIENT; ISCHEMIC HEART DISEASE; MONOTHERAPY; PRESCRIPTION; PRIMARY MEDICAL CARE; UNITED KINGDOM; AGED; BLOOD; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY;

AGED; CHOLESTEROL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PYRROLES; RETROSPECTIVE STUDIES;

EID: 84896455094     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.890926     Document Type: Article

References (70)

1. Allender S, Scarborough P, Peto V, et al.; for the British Heart Foundation Health Promotion Research Group and Health Economics Research Centre. European Cardiovascular Disease Statistics. 2008. Available at: http:// www.herzstiftung.ch/uploads/media/European-cardiovascular-disease- statistics-2008.pdf [Last accessed 14 February 2014]
2. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52
3. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
5. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
6. Walley T, Folino-Gallo P, Stephens P, et al. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. Br J Clin Pharmacol 2005;60:543-51
7. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37
8. Townsend N, Wickramasinghe K, Bhatnagar P, et al. Coronary Heart Disease Statistics: A Compendium of Health Statistics. 2012. London: British Heart Foundation Health Promotion Research Group, Department of Public Health, University of Oxford, 2012
9. NHS Employers. 2013/14 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 2013/14. NHS Confederation (Employers) Company Ltd. No. 5252407. Ref: EINF28001. Available at: http://www.nhsemployers.org/Aboutus/ Publications/Pages/qof-2013-14.aspx [Last accessed 14 February 2014]
10. McGovern MP, Boroujerdi MA, Taylor MW, et al. The effect of the UK incentive- based contract on the management of patients with coronary heart disease in primary care. Fam Pract 2008;25:33-9
11. MacBride-Stewart SP, Elton R, Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Fam Pract 2008;25:27-32
12. Public Health Policy & Strategy Unit/NHS Commissioning Unit. Living Well for Longer: A Call to Action to Reduce Avoidable Premature Mortality. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment- data/file/181103/Living-well-for-longer.pdf [Last accessed 14 February 2014]
13. World Health Organization. Prevalence of high cholesterol levels (4/= 5.0 mmol/L), from WHO, standardised for age. Available at: http://apps. who.int/gho/data/# [Last accessed 16 July 2013]
14. Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 2013;381:997-1020
15. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1-52
16. National Institute for Clinical Excellence and National Collaborating Centre for Primary Care. NICE Clinical Guideline 67. Lipid modification. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at: http:// www.nice.org.uk/nicemedia/pdf/CG67NICEguideline.pdf [Last accessed 14 February 2014]
17. National Institute for Clinical Excellence and National Collaborating Centre for Primary Care. NICE Clinical Guideline
18. Type 2 Diabetes. The Management of Type 2 Diabetes. Available at: http://www.nice.org.uk/nicemedia/pdf/ CG87NICEguideline.pdf [Last accessed 14 February 2014]
19. Wong IC, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005;59:750-5
20. Brankin E, Walker M, Lynch N, et al. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006;22:1249-56
21. Ackroyd R, Watson DI, Majeed AW, et al. Randomized clinical trial of laparoscopic versus open fundoplication for gastro-oesophageal reflux disease. Br J Surg 2004;91:975-82
22. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304
23. Eggleston A, Wigerinck A, Huijghebaert S, et al. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998;42:13-16
24. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Safety 2006;15:565-77
25. Vink NM, Klungel OH, Stolk RP, et al. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf 2009;18:159-65
26. Medicines and Healthcare Regulatory Agency. Drug safety update: simvastatin: increased risk of myopathy at high dose (80 mg). May 2010. Available at: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ CON085169 [Last accessed 14 February 2014]
27. U.S. Food and Drug Administration. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 8 June 2011. Available at: http://www.fda. gov/drugs/drugsafety/ucm256581.htm [Last accessed 14 February 2014]
28. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation November 12, 2013. Published online before print. doi:10.1161/01.cir.0000437738. 63853.7a
29. National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolemia. NICE Technology Appraisal Guidance 132. Available at: http:// www.nice.org.uk/nicemedia/live/11886/38799/38799.pdf [Last accessed 14 February 2014]
30. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-92
31. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-56
32. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32
33. Gitt AK, Drexel H, Feely J, et al. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012;19:221-30
34. Leiter LA, Lundman P, da Silva PM, et al. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabet Med 2011;28:1343-51
35. Lee KK, Lee VW, Chan WK, et al. Cholesterol goal attainment in patients with coronary heart disease and elevated coronary risk: results of the Hong Kong hospital audit study. Value Health 2008;11(Suppl 1):S91-8
36. Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83
37. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389-99
38. Ose L, Skjeldestad FE, Bakken IJ, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs 2006;6:121-8
39. Goodman SG, Langer A, Bastien NR, et al. Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS). Can J Cardiol 2010;26:e330-5
40. da Silva PM, Cardoso SM. Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol 2011;30:47-63
41. Gonzalez-Juanatey JR, Millan J, Alegria E, et al. [Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain Study]. Rev Esp Cardiol 2011; 64:286-94
42. Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events - results of the DYSlipidemia International Study (DYSIS). Wien Klin Wochenschr 2011;123:611-17
43. Horgan S, Crowley J, Feely J, et al. Prevalence of dyslipidaemia in statintreated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS). Ir J Med Sci 2011;180:343-9
44. Pettersson B, Ambegaonkar B, Sazonov V, et al. Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA). BMC Public Health 2010;10:737
45. Jameson K, Amber V, D'Oca K, et al. Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study. Int J Clin Pract 2013; 67:1228-37
46. Phatak H, Wentworth C, Sazonov V, et al. Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009;202:225-33
47. Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin 2008;24:1951-63
48. Paragh G, Mark L, Zamolyi K, et al. Lipid-modifying therapy and attainment of cholesterol goals in Hungary: the return on expenditure achieved for lipid therapy (REALITY) study. Clin Drug Investig 2007;27:647-60
49. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63
50. Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
51. Jukema JW, Chiang CW, Ferrieres J, et al. Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2. Curr Med Res Opin 2010;26:2589-97
52. Santos RD, Waters DD, Tarasenko L, et al. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Am Heart J 2009;158:860-6
53. Rodriguez F, Santos RD, Messig M, et al. Comparison of lipid profiles and attainment of lipid goals in patients565 years versus patients4/=65 years (from the Lipid Treatment Assessment Project [L-TAP] 2). Am J Cardiol 2012;109:1738-42
54. Park JE, Chiang CE, Munawar M, et al. Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol 2012;19:781-94
55. Ambegaonkar BM, Bash LD, Chirovsky DR, et al. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada. Eur J Intern Med 2013;24:656-63
56. Phillips LS, Twombly JG. It's time to overcome clinical inertia. Ann Intern Med 2008;148:783-5
57. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med 2001;135:825-34
58. Mohan AV, Phillips LS. Clinical inertia and uncertainty in medicine. JAMA 2011;306:383-4
59. Lindgren P, Borgstrom F, Stalhammar J, et al. Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs. Int J Clin Pract 2007;61:1410-14
60. Cohen JD, Brinton EA, Ito MK, et al. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012;6:208-15
61. Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/ AHA clinical practice guidelines. JAMA 2009;301:831-41
62. Chopra I, Kamal KM, Candrilli SD. Variations in blood pressure and lipid goal attainment in primary care. Curr Med Res Opin 2013;29:1115-25
63. Clark LT, Maki KC, Galant R, et al. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. J Gen Intern Med 2006;21:320-6
64. Virani SS, Woodard LD, Landrum CR, et al. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J 2011;161:1140-6
65. Forey BA, Fry JS, Lee PN, et al. The effect of quitting smoking on HDLcholesterol - a review based on within-subject changes. Biomark Res 2013;1:26
66. Ortega JF, Fernandez-Elias VE, Hamouti N, et al. Increased blood cholesterol after a high saturated fat diet is prevented by aerobic exercise training. Appl Physiol Nutr Metab 2013;38:42-8
67. Jenkins DJ, Jones PJ, Lamarche B, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. JAMA 2011;306:831-9
68. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001; 52:575-87
69. Wilson PW, Hoeg JM, D'Agostino RB, et al. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med 1997;337:516-22
70. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64